CK Life Sciences Int'l. (Holdings) Inc risk profile
64 Stretched several inputs deteriorating together
Measured 1 September 2026 from LSI's filed statements. Recomputed nightly.
64 (Stretched), driven by Leverage and coverage at 88, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 81 | Acute | Stable | Drawdown from the 52-week high — 42.7% |
| Operating pressure | 54 | Elevated | Worsening | Costs outgrowing revenue — +3.8 percentage points |
| Cash conversion | 83 | Acute | Worsening | Capital spending against operating cash — 1.33x |
| Leverage and coverage | 88 | Acute | Stable | Net debt to EBITDA — 12.18x |
| Competitive position | 52 | Elevated | Stable | Revenue-growth gap against peers — -27.1 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for CK Life Sciences Int'l. (Holdings) Inc